Product Description
Pagoclone is a novel cyclopyrrolone compound that acts as a selective modulator of gamma-aminobutyric acid (GABA) receptors, particularly the GABA(A) receptor. It exhibits partial agonist activity, influencing inhibitory neurotransmission in the central nervous system. Due to its distinctive pharmacological properties, pagoclone has attracted attention as a potential treatment for speech disorders, especially stuttering. Research has explored its ability to improve speech fluency by regulating neuronal activity and reducing excessive neural excitation. In addition, its effects on anxiety-related symptoms have also been investigated. However, its clinical effectiveness and long-term safety require further evaluation before broader therapeutic applications can be established.
Chemical Properties
| Boiling point | 582.1±50.0 °C(Predicted) |
| density | 1.273±0.06 g/cm3(Predicted) |
| pka | 1.62±0.30(Predicted) |
| InChI | InChI=1S/C23H22ClN3O2/c1-14(2)7-10-16(28)13-19-17-5-3-4-6-18(17)23(29)27(19)21-12-9-15-8-11-20(24)25-22(15)26-21/h3-6,8-9,11-12,14,19H,7,10,13H2,1-2H3 |
| InChIKey | HIUPRQPBWVEQJJ-UHFFFAOYSA-N |
| SMILES | C1(=O)C2=C(C=CC=C2)C(CC(=O)CCC(C)C)N1C1=CC=C2C(=N1)N=C(Cl)C=C2 |
Product Usage
Pagoclone is a selective modulator of gamma-aminobutyric acid (GABA) receptors that has been investigated for its potential to reduce stuttering. It belongs to the cyclopyrrolone class of compounds and acts as a partial agonist of the GABA(A) receptor. By influencing inhibitory neurotransmission in the central nervous system, pagoclone may help regulate neuronal activity and improve speech fluency. Its distinctive pharmacological properties have attracted interest in the development of potential treatments for speech disorders. In addition, its effects on anxiety-related symptoms have also been explored. However, further clinical studies are needed to establish its therapeutic effectiveness and long-term safety.
